Abstract:Apatinib is a tyrosine kinase inhibitor which selectively inhibits VEGFR-2 and also represents mild inhibition to PDGFR, c-Kit and c-src. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis and tumor cell proliferation. Previous clinical trials have demonstrated its obvious antitumor activity in various cancer type. Thus we designed this phase II, open-label, single-armed, prospective study (NCT02515435) to investigate the efficacy and safety of apatinib for heavily treated, advanced non-squamous NSCLC patients who are not applicable to current standardized therapy or other clinical trials. We prospectively enrolled 40 patients with previously heavily treated advanced non-squamous NSCLC. All patients received apatinib with a dose of 500mg, q.d., p.o. Efficiency was evaluated initially 4 weeks later and then every 8 weeks until disease progression, death, or unacceptable toxicity. The primary end point of this study was overall response rate (ORR). The secondary end points were progression-free survival (PFS), overall survival (OS). Forty patients were enrolled in the study with a median age of 61. 15% of patients received apatinib as second-line therapy, 40% of patients received apatinib as third-line therapy, and 60% as forth-line to twelfth-line therapy. Nine patients were found with activated EGFR mutation. Among all the enrolled patients, 38 patients had clinical evaluation and the other 2 received treatment of apatinib less than one month. Within 33 patients who had available image efficiency, 6 were identified as PR,17 SD and 10 PD, no CR was observed. The ORR was 18.18 %, the DCR was 69.69%. The ORR for patients with EGFR mutation positive and negative were 25% and 16% separately. The median PFS was 3.22 months (95% CI, 2.20-4.17 months). Among them, 6 patients received the treatment of apatinib more than five months. The 6-month OS rate was 76.98% (95% CI, 61.68%-92.27%), the 12-month OS rate was 57.48% (95% CI, 28.75%-86.20%). Common treatment-related adverse events were proteinuria (25%), hypertension (17.5%), and hand-foot-skin reaction (HFSR)(27.5%). Severe adverse events included grade 3 hypertension (5%), HFSR (5%), and thrombocytopenia (5%), no grade 4 or 5 adverse events were observed. No un-expected adverse events were found. Apatinib as a monotherapy had a promising overall response together with an acceptable side effect in patients with previously heavily treated advanced non-squamous NSCLC. A phase III study comparing apatinib monotherapy with placebo as 3rd/4th setting in advanced non-squamous NSCLC is ongoing to further evaluated the efficacy of apatinib (NCT02332512).

Safety of Apatinib As Third-Line or Beyond Treatment in Advanced or Metastatic Gastric Cancer: Results from a Multicenter Phase IV Study (Ahead-G201).

Apatinib As Third-Line or Beyond Therapy in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: an Open-Label, Multicenter, Post-Marketing Phase IV Study (Ahead-G201)

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study.

An Open Label, Multicenter, Noninterventional Study of Apatinib in Advanced Gastric Cancer Patients (AHEAD-G202).

P1.12-01 A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC after Second/Third-Line Chemotherapy

Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results from a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial.

Apatinib In Patients With Adenocarcinoma Of Stomach Or Gastroesophageal Junction: A Prospective, Multicenter, Non-Interventional Study (Ahead-G202)

Clinical Benefit of Continuing Apatinib Beyond Progression in Advanced or Metastatic Gastric Cancer.

Efficacy and safety of apatinib in treatment of gastric cancer: A real-world study.

Exploration of Patients with Gastric Cancer Who Benefit from Apatinib: an Updated Real-World Study.

Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)

Prospective, Multicenter, Noninterventional And Registry Clinical Study Of Apatinib In Patients With Advanced Gastric Cancer.

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Impact of Time to Progression on First-Line Therapy on Clinical Outcomes in Advanced Gastric Cancer Treated with Apatinib: Data from a Phase IV Study (Ahead-G201).

Development of Non-Hematological Adverse Events in Apatinib-Treated Gastric Cancer and Their Association with Clinical Outcome: Results from a Phase IV Study.

682PIdentification of patients who benefit from apatinib in advanced gastric cancer: Data derived from a real-world study

A Randomized, Double-Blind, Multicenter, Phase Ii, Three-Arm, Placebo-Control Study of Apatinib As Third-Line Treatment in Patients with Metastatic Gastric Carcinoma.

Apatinib In The Treatment Of Non-Operable Or Advanced Gastric Cancer: Evidence Of Efficacy And Safety In A Real-World Study.